臺灣博碩士論文加值系統

跨國藥廠以研發、銷售專利藥為核心能力，但近年來由於陸續面臨專利到期之壓力，加上政府積極調降醫療成本，許多跨國藥廠開始考慮尋找合作對象，生產品牌學名藥 (或授權學名藥) 以做因應。S品牌為跨國製藥集團下的學名藥部門，是第一個進入台灣市場的品牌學名藥廠商。本研究根據文獻探討與資料庫分析，評估S品牌在台灣之4P組合優勢。結果顯示，台灣醫療機構普遍重視學名藥品質，S品牌藥物製程已獲得國際標準PIC/S GMP認證，有利其在台灣發展。由於S品牌耕耘跨國市場，具備規模經濟並享有成本優勢，有利於價格競爭，但須另外考慮貿易成本與藥證申請障礙。文獻與實證皆指出，於專利到期前提早取得藥證，可享推廣之先進者優勢。S品牌專注於經營醫院通路，本土藥廠則以診所通路為主，對於主要在醫院使用之藥品種類，S品牌能展現通路優勢，惟醫院有時偏好使用原廠藥，學名藥進入較不易。目前S品牌在台灣尚未普遍銷售母公司產品之學名藥，因此未能評估此方式是否具競爭優勢。健保局決定在2014年7月對給付超過15年之專利到期藥品，實施和PIC/S GMP學名藥同價格之政策，品牌學名藥此時可作為跨國藥廠延續專利到期產品生命週期的有效策略之一。

Transnational pharmaceutical firms focus on the R&;D and promotion of branded drugs as core competency. However, facing increasing challenges from upcoming loss of exclusivity (LOE) on blockbuster drugs as well as aggressive healthcare cost containment measures, many transnational pharmaceutical firms develop their own generic subsidiaries or partner with low-cost pharmaceutical companies to introduce branded generics (or authorized generics). S brand, the generic pharmaceuticals division of a transnational pharmaceutical firm, was the first branded generic company in Taiwan. Based on article researches and data analysis, this study assesses the competitive advantages of S brand in 4P mix. The results show that medical institutions in Taiwan generally concern about the quality of generic, which is in favor of PIC/S GMP-certified manufacturers, such as S brand. Producing and marketing large quantities of generic enables transnational S brand to generate economies of scale or cost advantage over competitors. However, the barriers to trading and licensing should be considered. According to theory and empirical evidence, generic permitted as soon as the original drug goes off-patent gains first-mover advantage in promotion. S brand focuses on hospital channel, while clinic channel is favored by local pharmaceutical industries, it is efficient for S brand to promote generic primarily used in hospitals. In some cases, hospital channel is difficult for generic entry due to brand loyalty to original drug. Currently, S brand rarely promotes the authorized generic version of parent company’s drugs in Taiwan; therefore, we cannot evaluate the competitive advantage of that. Taiwan's National Health Insurance has decided to unify the prices of PIC/S GMP-certified generic and original drug reimbursed over 15 years in July 2014. Brand generic might be an effective strategy for transnational pharmaceutical firms to extend the product life cycle of patent-off drugs.

中文摘要 I
英文摘要 II
誌謝 IV
目錄 V
表目錄 VI
圖目錄 VII
第一章、緒論 1
1.1 研究背景 1
1.2 研究動機與目的 5
第二章、文獻探討 6
2.1全球藥品市場分析 6
2.2台灣全民健康保險制度 7
2.3台灣藥品市場分析 10
2.4 4P組合行銷策略 13
第三章、研究方法 14
3.1研究流程 14
3.2研究對象 17
3.3研究範圍 18
第四章、實證結果 19
4.1 S品牌在台灣之銷售趨勢分析 19
4.2 4P組合分析–Ceftriaxone成分 23
4.3 4P組合分析- Amoxycillin/ Clavulanate成分 26
4.4 4P組合分析–Piperacillin/ Tazobactam成分 29
4.5 4P組合分析–Atorvastatin成分 32
4.6 4P組合分析–Simvastatin成分 37
第五章、研究結論與建議 43
5.1 結論 43
5.2 建議 45
參考文獻 46
中文部分 46
英文部分 47

[中文部分]
王淑玄(2012)，影響藥廠新推出學名藥銷售績效之原因:以台灣學名藥廠為例，長庚大學工商管理學系碩士論文。
全民健康保險藥價基準(1999)，行政院衛生福利部，網址：http://www.nhi.gov.tw/。
全民健康保險藥品價格調整作業辦法(2013)，行政院衛生福利部，網址：http://www.nhi.gov.tw/。
行政院經濟建設委員會(1990)，全民健康保險與社會福利政策發展相關性研究，台大社會系，18-19。
行政院衛福部編(2004)，全民健保改陏綜論，台北：行政院衛福部。
西藥製劑製造工廠實施國際GMP標準 (PICS GMP) 之時程(2007)，衛生福利部食品藥物管理署，網址：http://www.fda.gov.tw/
巫文玲、羅淑慧(2010)，醫藥產業年鑑2010，台北：財團法人生物技術開發中心
巫文玲、賴瓊雅、廖美智、羅淑慧、湯谷清、吳品頤、許毓真、黃詩芳、陳正揚、陳秋玲、黃雅亭(2013)，醫藥產業年鑑2013，台北：財團法人生物技術開發中心
呂發財(2011)，影響各層級醫院選擇學名藥之相關因素探討，長庚大學管理學院碩士學位學程在職專班醫務管理組碩士論文。
林宗賢(2009)，生技製藥產業授權發展概況，生物醫藥。
洪賢智(2001)，廣告管理與實務，台北﹕五南圖書出版有限公司。
陳勤仁(2011)，學名藥各通路成功擴散之關鍵因素探討 ─以高血壓用藥為例，國立臺北大學企業管理學系碩士論文。
湯谷清(2012)，我國明星產業競爭優勢及市場利基研究-生技及國際醫療，台北：財團法人生物技術開發中心
黃肇明、朱澤民(2009)，全民健保「藥價黑洞」知多少，主計月刊，第637 期， 62 頁。
楊志良等編著(2008)，健康保險，華格那企業。
衛生福利部中央健康保險署全球資訊網(2013) ，網址：http://www.nhi.gov.tw/
羅淑慧(2013)，2013年第二季我國製藥產業回顧與展望，台北：財團法人生物技術開發中心。
蕭詩婧(2004)，總額預算下，台灣學名藥市場的策略研究----以降血脂劑 (Statin)為例，國立陽明大學醫務管理研究所碩士論文。

[English]
A Look At Abbott's Branded Generic Drug Business. Published Oct 04 2013 by BioPortfolio. http://www.bioportfolio.com/news/article/1670781/A-Look-At-Abbotts-Branded-Generic-Drug-Business.html
AstraZeneca Extends Branded Generics Capability with Torrent Agreement, AstraZeneca website. http://www.astrazeneca.com/Media/Press-releases/Article/20100311--AstraZeneca-Extends-Branded-Generics-Capability-With-
Caves, R., Whinston, M. and Hurwitz, M. (1991), Patent Expiration, Entry, and Competition in the US Pharmaceutical Industry. Brookings Papers on Economic Activity: Microeconomics, pp. 1–66.
Chandler, L.L. and Samaroo, H.D. (2010), Pfizer and the Greenstone Brand: A Sustainable Competitive Advantage? Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing, 10(2): 155-164.
Clinical trials: A Chance to Try Evolving Therapies, MayoClinic website. http://www.mayoclinic.com/health/clinical-trials/DI00033
Drug Discovery and Development, PhRMA website. http://www.phrma.org/innovation/clinical-trials
Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act) (1984), Pub. L. No. 98-417, 98 Stat. 1585.
Ellison, S. F. and Snyder, C. M. (2010), Countervailing Power in Wholesale Pharmaceuticals. Journal of Industrial Economics, 57: 32–53.
Frank, R. G. and Salkever, D. S. (1997), Generic Entry and the Pricing of Pharmaceuticals. Journal of Economics and Management Strategy, 6(1): 75–90.
Glaxo to Sell Branded Generics in Emerging Markets. Published Jul 23 2008 by Reuters London. http://uk.mobile.reuters.com/article/mergersNews/idUKL2388140620080723.
Goldsmith, J. (2002), Essays on Consumer Access to New Products and Technologies. Doctoral Dissertation, University of Maryland.
Grabowski, H. G. and Vernon, J. M. (1992), Brand Loyalty, Entry, and Price Competition in Pharmaceutical After The 1984 Drug Act, Journal of Law and Economics, 35(2): 331–50.
Greenstone website. http://www.greenstonellc.com/
Harrison, C. (2013). Dangling From the Patent Cliff. Nature Reviews Drug Discovery, 12: 14-15.
IMS Health website. http://www.imshealth.com/
Kotler, P. (1967). Marketing Management: Analysis, Planning and Control. Englewood Cliffs, N.J., Prentice-Hall.
Liu, Y. M. and Cheng, J. S. (2012). Determinants of Generic Entry in The Regulated Taiwanese Prescription Drug Market. Health Policy, 108: 228– 235.
Liu, Y. M., Yang, Y. H. K. and Hsieh, C. R. (2009). Financial Incentives and Physicians’ Prescription Decisions on the Choice Between Brand-Name and Generic Drugs: Evidence From Taiwan. Journal of Health Economics, 28: 341–349.
McCarthy, E. J. (1960). Basic Marketing: A Managerial Approach. Homewood IL: Irwin.
Merck is Focused on Delivering High-Quality Biosimilar Products to the Patients Who Need Them and Capitalizing on the Patent Expirations of a Number of Currently Marketed Recombinant Biologic Medicines, Merck website. http://www.merckresponsibility.com/focus-areas/access-to-health/research-development/merck-biosimilars/
Novartis website. http://www.novartis.com/products/sandoz.shtml
Reiffen, D. and Ward, M. R. (2007), Branded Generics as a Strategy to Limit Cannibalization. Managerial and Decision Economics, 28(4): 251-265.
Scott Morton, F. (1996), Entry Decisions in the Generic Pharmaceutical Industry. RAND Journal of Economics, 30: 421–440.
Taiwan: Top 20 Rankings by Sales Value of Both Local and Multinational Companies, PharmaBoardroom website. http://www.pharmaboardroom.com/article/taiwan-top-20-ranking-of-multinational-companies
The Changing Face of the Top 10 Pharmaceutical Companies (2013), IMS Health website. http://www.imshealth.com/deployedfiles/ims/Global/Asia%20Pacific/Content/Insights/Top10%20Pharma%20Companies%20WP%20final_for%20clients.pdf
The Global Use of Medicines: Outlook Through 2016 (2012), IMS Health website. http://www.imshealth.com/deployedfiles/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/Global%20Use%20of%20Meds%202011/Medicines_Outlook_Through_2016_Report.pdf.
To Respond to the Needs of the Greatest Possible Number of Patients Throughout the World, Sanofi Has Intensified its Strategy of Diversification on the Generics Market, Sanofi website. http://en.sanofi.com/products/generics/generics.aspx